Etanercept
Mechanism :
Etanercept binds specifically to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors. TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in involved tissues and fluids of patients with RA, psoriatic arthritis, ankylosing spondylitis (AS), and plaque psoriasis.
Indication :
- Juvenile idiopathic arthritis
- Psoriasis
Contraindications :
Contraindicated in patients with current or previous tuberculosis, previous or present sepsis, prosthetic joint still in situ, malignancy or pre-malignancy states, immunodeficiency, hypersensitivity to the active substance or to any of the excipients. Caution should be exercised in patients with pre-existing or recent onset of CNS demyelinating disease. Etanercept should be used with caution in patients with a history of allergies, asthma, or allergic-type phenomena associated with other drugs.
Dosing :
Psoriasis:
Under 4 years: Safety and efficacy not established.
Above 4 years, under 63 kg: 0.8 mg/kg subcutaneously one a week; not to exceed 50 mg weekly.
Above 4 years, over 63 kg: 50 mg subcutaneously one a week.
Juvenile Rheumatoid Arthritis:
Under 2 years: Safety and efficacy not established.
Above 2 years, under 63 kg: 0.8 mg/kg subcutaneously one a week; not to exceed 50 mg weekly.
Above 2 years, over 63 kg: 50 mg subcutaneously one a week.
Adverse Effect :
Erythema, itching, pain and swelling at the injection site, nausea and vomiting, abdominal pain, headache, dizziness, asthenia, rash, infections.
Interaction :
Vaccinations: Live vaccines should not be given concurrently with etanercept.
Hepatic Dose :
No dosage adjustments are recommended.